Table 3.
No. | Group of metabolites | Metabolite | P max (PA mL–1) | AUC (0–24 h, PA mL–1) | ||
---|---|---|---|---|---|---|
Sham | OVX | Sham | OVX | |||
BS‐CGJ | BS‐CGJ | BS‐CGJ | BS‐CGJ | |||
1 | Isoflavone | Genistein | – | – | <0.05 | <0.01 |
2 | Daidzein | – | – | <0.001 | – | |
3 | Glycitein | – | – | – | – | |
4 | Phase I (Liver) | 3‐Hydroxygenistein | – | – | – | <0.05 |
5 | 6‐Hydroxydaidzein | – | – | – | <0.05 | |
6 | Phase II (Liver) | Genistein 4′‐glucuronide | – | <0.001 | – | – |
7 | Genistein 7‐glucuronide | – | – | – | – | |
8 | Genistein 4′‐sulfate | <0.05a) | – | <0.05a) | <0.05 | |
9 | Genistein 7‐sulfate | – | – | – | – | |
10 | Daidzein 7‐glucuronide | – | – | <0.01a) | – | |
11 | Daidzein 4′‐sulfate | <0.001a) | – | <0.01a) | – | |
12 | Methylgenistein | – | <0.001a) | – | – | |
13 | Formononetin | – | – | <0.01a) | <0.001a) | |
14 | Gut‐mediated metabolites | Dihydrogenistein | – | – | – | <0.05 |
15 | Dihydrogenistein sulfate | – | – | – | <0.05 | |
16 | Dihydrodaidzein | – | – | – | <0.05 | |
17 | Dihydrodaidzein sulfate | – | – | – | <0.05 | |
18 | Equol 7‐glucuronide | – | – | <0.01a) | <0.05 | |
19 | Equol 4′‐sulfate | <0.01a) | <0.001a) | <0.05a) | – | |
20 | 5‐hydroxy equol | – | – | – | <0.05 | |
21 | Hippuric acid | – | – | – | – | |
22 | 4‐hydroxybenzoic acid | – | – | <0.01a) | <0.05a) | |
23 | 2,6‐Dimethoxy benzoic acid | – | – | – | – | |
24 | Caffeic acid | – | – | – | <0.05a) | |
25 | Methyl caffeic acid | – | – | – | <0.05a) | |
26 | Fumaric acid | – | – | – | – | |
27 | 4‐Ethylphenol | – | – | – | – | |
28 | Glutaric acid | – | – | – | <0.05 | |
29 | 2‐Phenylpropanoic acid | – | – | – | – | |
30 | p‐Coumaric acid | – | – | <0.01a) | <0.05 | |
31 | Gallic aicd | – | – | – | <0.05 | |
32 | Ferulic acid | – | – | – | – | |
33 | Resorcinol | – | – | – | – | |
34 | Resorcinol sulfate | – | – | – | – |
a)Metabolites that were significantly increased in the BS‐treated group compared with the CGJ‐treated group.